111 related articles for article (PubMed ID: 33501813)
1. [3D organization profiling of human hepatocellular carcinoma cell line PLC/PRF/5 in comparison with normal human liver cell line L02 by in situ Hi-C].
Hu H; Chai X; Wang L; Cai J; Lan F
Sheng Wu Gong Cheng Xue Bao; 2021 Jan; 37(1):331-341. PubMed ID: 33501813
[TBL] [Abstract][Full Text] [Related]
2. The effect of CTCF binding sites destruction by CRISPR/Cas9 on transcription of metallothionein gene family in liver hepatocellular carcinoma.
Gong W; Liu Y; Qu H; Liu A; Sun P; Wang X
Biochem Biophys Res Commun; 2019 Mar; 510(4):530-538. PubMed ID: 30738580
[TBL] [Abstract][Full Text] [Related]
3. Regulation of transforming growth factor-beta1 gene expression and cell proliferation in human hepatocellular carcinoma cells (PLC/PRF/5) by tamoxifen.
Gong Y; Zhang M; Minuk GY
J Lab Clin Med; 1999 Jul; 134(1):90-5. PubMed ID: 10402064
[TBL] [Abstract][Full Text] [Related]
4. Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity.
Liu ZH; Lian BF; Dong QZ; Sun H; Wei JW; Sheng YY; Li W; Li YX; Xie L; Liu L; Qin LX
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2360-2368. PubMed ID: 29408647
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic silencing of TMEM176A activates ERK signaling in human hepatocellular carcinoma.
Li H; Zhang M; Linghu E; Zhou F; Herman JG; Hu L; Guo M
Clin Epigenetics; 2018 Nov; 10(1):137. PubMed ID: 30400968
[TBL] [Abstract][Full Text] [Related]
6. Fibronectin plays a major role in hypoxia-induced lenvatinib resistance in hepatocellular carcinoma PLC/PRF/5 cells.
Takahashi M; Okada K; Ouch R; Konno T; Usui K; Suzuki H; Satoh M; Kogure T; Satoh K; Watanabe Y; Nakamura H; Murai Y
Pharmazie; 2021 Dec; 76(12):594-601. PubMed ID: 34986955
[TBL] [Abstract][Full Text] [Related]
7. Identification of c-Yes expression in the nuclei of hepatocellular carcinoma cells: involvement in the early stages of hepatocarcinogenesis.
Nonomura T; Masaki T; Morishita A; Jian G; Uchida N; Himoto T; Izuishi K; Iwama H; Yoshiji H; Watanabe S; Kurokohchi K; Kuriyama S
Int J Oncol; 2007 Jan; 30(1):105-11. PubMed ID: 17143518
[TBL] [Abstract][Full Text] [Related]
8. The PLC/PRF/5 human hepatoma cell line. II. Chromosomal assignment of hepatitis B virus integration sites.
Bowcock AM; Pinto MR; Bey E; Kuyl JM; Dusheiko GM; Bernstein R
Cancer Genet Cytogenet; 1985 Sep; 18(1):19-26. PubMed ID: 2992762
[TBL] [Abstract][Full Text] [Related]
9. Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas.
Ding X; He M; Chan AWH; Song QX; Sze SC; Chen H; Man MKH; Man K; Chan SL; Lai PBS; Wang X; Wong N
Gastroenterology; 2019 Dec; 157(6):1630-1645.e6. PubMed ID: 31560893
[TBL] [Abstract][Full Text] [Related]
10. Silencing HOXD10 by promoter region hypermethylation activates ERK signaling in hepatocellular carcinoma.
Guo Y; Peng Y; Gao D; Zhang M; Yang W; Linghu E; Herman JG; Fuks F; Dong G; Guo M
Clin Epigenetics; 2017; 9():116. PubMed ID: 29075359
[TBL] [Abstract][Full Text] [Related]
11. EYA4 inhibits hepatocellular carcinoma growth and invasion by suppressing NF-κB-dependent RAP1 transactivation.
Mo SJ; Hou X; Hao XY; Cai JP; Liu X; Chen W; Chen D; Yin XY
Cancer Commun (Lond); 2018 Apr; 38(1):9. PubMed ID: 29764501
[TBL] [Abstract][Full Text] [Related]
12. Cell line-specific features of 3D chromatin organization in hepatocellular carcinoma.
Kim Y; Yang H; Lee D
Genomics Inform; 2023 Jun; 21(2):e19. PubMed ID: 37704209
[TBL] [Abstract][Full Text] [Related]
13. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
[TBL] [Abstract][Full Text] [Related]
14. Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.
D'Alessandro R; Refolo MG; Lippolis C; Carella N; Messa C; Cavallini A; Carr BI
Cell Oncol (Dordr); 2018 Jun; 41(3):283-296. PubMed ID: 29470830
[TBL] [Abstract][Full Text] [Related]
15. Loss of tumor suppressor IGFBP4 drives epigenetic reprogramming in hepatic carcinogenesis.
Lee YY; Mok MT; Kang W; Yang W; Tang W; Wu F; Xu L; Yan M; Yu Z; Lee SD; Tong JHM; Cheung YS; Lai PBS; Yu DY; Wang Q; Wong GLH; Chan AM; Yip KY; To KF; Cheng ASL
Nucleic Acids Res; 2018 Sep; 46(17):8832-8847. PubMed ID: 29992318
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia disrupts the expression levels of circadian rhythm genes in hepatocellular carcinoma.
Yu C; Yang SL; Fang X; Jiang JX; Sun CY; Huang T
Mol Med Rep; 2015 May; 11(5):4002-8. PubMed ID: 25591621
[TBL] [Abstract][Full Text] [Related]
17. Expression of angiogenic factors in hepatocarcinogenesis: Identification by antibody arrays.
Nomura T; Morishita A; Jian G; Mimura S; Kato K; Nomura K; Tani J; Miyoshi H; Yoneyama H; Sakamoto T; Fujita K; Maeda E; Kobara H; Mori H; Iwama H; Masaki T
Oncol Rep; 2013 Nov; 30(5):2476-80. PubMed ID: 23970062
[TBL] [Abstract][Full Text] [Related]
18. Parkin gene alterations in hepatocellular carcinoma.
Wang F; Denison S; Lai JP; Philips LA; Montoya D; Kock N; Schüle B; Klein C; Shridhar V; Roberts LR; Smith DI
Genes Chromosomes Cancer; 2004 Jun; 40(2):85-96. PubMed ID: 15101042
[TBL] [Abstract][Full Text] [Related]
19. Identification of cancer stem cells from hepatocellular carcinoma cell lines and their related microRNAs.
Xu Y; Xie Y; Wang X; Chen X; Liu Q; Ying M; Zheng Q
Oncol Rep; 2013 Nov; 30(5):2056-62. PubMed ID: 24002436
[TBL] [Abstract][Full Text] [Related]
20. [BORIS Regulates SOCS3 Expression Through Epigenetic Mechanisms in Human Hepatocellular Carcinoma Cells].
He JY; Liu QY; Wei L; Liu ZJ; Huang Y; Yu XQ; Li B; Qin Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 Jan; 49(1):1-7. PubMed ID: 29737080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
